Table 1

Clinicopathologic variables and surival.

Characteristic

Patients

(n)

Patients

(%)

Median survival (months)

5-Year survival

(%)

P


Age

≤ 20 years

7

9

NR

57

0.479

21-60 years

36

45

63

53

> 60 years

37

46

36

44

Sex

Male

35

44

63

50

0.847

Female

45

56

57

49

Nationality

Norwegian

59

74

38

48

0.646

Russian

21

26

127

52

Histology

Undifferentiated pleomorphic sarcoma

20

25

127

57

0.025

Leiomyosarcoma

21

26

67

52

Angiosarcoma

7

9

15

29

Liposarcoma

6

8

36

50

Rhabdomyosarcoma

6

8

32

50

Synovial sarcoma

6

8

31

50

MPNST

5

6

NR

80

MF/MFT

4

5

15

50

Other STS

5

6

11

0

Tumor localization

Extremities

31

39

123

61

0.447

Trunk

15

19

32

47

Retroperitoneum

11

14

57

42

Head/Neck

5

6

15

20

Pelvis

18

23

22

41

Tumor size

≤ 5 cm

26

33

67

54

0.800

5-10 cm

33

41

31

45

> 10 cm

20

25

80

53

Missing

1

1

Malignancy grade FNCLCC

1

15

19

NR

70

0.007

2

31

39

80

61

3

34

43

15

29

Tumor depth

Superficial

4

5

NR

100

0.046

Deep

76

95

32

46

Operated

Yes

73

91

75

54

< 0.001

No

7

9

5

0

Surgical margins

Wide

39

49

NR

67

< 0.001

Non-wide

41

51

18

32

Metastasis at diagnosis

No

65

81

80

57

< 0.001

Yes

15

19

11

14

Chemotherapy

No

59

74

36

46

0.147

Yes

21

26

NR

57

Radiotherapy

No

60

75

38

47

0.775

Yes

20

25

63

55


Prognostic clinicopathologic variables as predictors for disease-specific survival in soft tissue sarcomas with peritumoral capsule (univariate analysis, log rank test), N = 80 Abbreviations: MF/MFT, malignant fibroblastic/myofibroblastic tumors; MPNST, malignant peripheral nerve sheath tumor; STS, soft tissue sarcomas; NR, not reached Ninety-one percent (n = 73) underwent surgery. The 5-year survival with non-wide resection margins was 32% and with wide resection margins it was 67%.

Sorbye et al. BMC Clinical Pathology 2012 12:5   doi:10.1186/1472-6890-12-5

Open Data